Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo. Try Elite Free for 7 Days
Login Sign up free
Home Screener Maps Charts News Groups Insider Futures Forex Crypto Portfolio Calendar
Pricing

New feature:   Introducing the Finviz Matrix

Learn More
Market News Market Pulse Stocks News ETF News Crypto News

Celularity Inc.

Contributing Author

Recent Articles by Celularity Inc.

Aug-25
Celularity Provides Update Regarding Nasdaq Listing Compliance CELU CELU +9.94% GlobeNewswire
Jun-04
Celularity and Fountain Life Announce Availability of Cenplacel-L for Investigational Use Under New Florida Law, Establishing Scalable Pathway for Advancement of Placental-Derived Cell Therapies CELU GlobeNewswire
Jun-03
Celularity Releases CEO Letter to Shareholders CELU GlobeNewswire
Jun-03
Celularity Appoints Rick Gonzalez as Chief Commercial Officer CELU GlobeNewswire
May-29
Celularity Receives Nasdaq Notice Regarding Form 10-Q CELU CELU +5.94% GlobeNewswire
May-01
Celularity Announces Filing of Form 10-K, Regains Nasdaq Compliance and Highlights Continued Strategic Transformation CELU GlobeNewswire
Apr-21
Celularity Announces Closing of Transaction with NexGel CELU GlobeNewswire
Apr-17
Celularity Announces Receipt of Nasdaq Notice Regarding Late Form 10-K Filing CELU GlobeNewswire
Mar-12
Celularity Reiterates Strategic Commercialization Partnership with NEXGEL Focused on Building Biomaterials Franchise with Established Commercial Products and New 510(k) Pathway Product Opportunities CELU GlobeNewswire
Mar-10
Celularity Secures $35 Million Strategic License Deal, Strengthens Capital Position to Advance Longevity-Focused Strategy CELU +11.20% GlobeNewswire
Feb-10
Celularity Receives $12.2 Million from Sale of New Jersey Net Operating Losses CELU GlobeNewswire
Dec-26
Celularity CEO Comments on Centers for Medicare & Medicaid Services' Withdrawal of Skin Substitute Local Coverage Determinations CELU GlobeNewswire
Dec-22
Celularity Announces Closing of Financing Transactions CELU -8.97% GlobeNewswire
Dec-18
Celularity Reaches Binding Term Sheets on Financing Transactions to Support Its Strategic Vision CELU CELU +16.00% GlobeNewswire
Oct-30
Celularity and DefEYE, Inc. Partner to Advance Growth of Regenerative Therapies in Eye Care CELU GlobeNewswire
Oct-14
Celularity Announces Peer-Reviewed Publication of Phase 2 Clinical Trial Results Demonstrating the Safety and Efficacy of Human Placenta-Derived Cells (PDA-002) for Diabetic Foot Ulcers Complicated by Peripheral Artery Disease CELU +11.27% GlobeNewswire
Sep-03
Celularity Announces Filing of Form 10-Q Quarterly Reports for the First Quarter and the Second Quarter 2025, Confirmation of Nasdaq Listing Rule 5250(c)(1) Compliance CELU GlobeNewswire
Aug-22
Celularity Receives Nasdaq Notice Regarding Form 10-Q CELU GlobeNewswire
Aug-18
Celularity Completes Major Balance Sheet Restructuring, Retires All $41.6 Million in Senior Secured Debt CELU +19.25% GlobeNewswire
Jul-09
Celularity & Fountain Life Announce Partnership to Deliver Stem Cell Therapies Under New Florida Law CELU +12.17% GlobeNewswire
Jul-01
Celularity Hails New Florida Law Opening Patient Access to Stem Cell Therapies CELU GlobeNewswire
Jun-10
Celularity Announces Chief Financial Officer Transition CELU CELU -10.45% GlobeNewswire
Jun-02
Celularity Announces Publication Advancing Ocular Surface Reconstruction with Tri-Layer Amniotic Membrane Technology CELU +6.16% GlobeNewswire
May-30
Celularity Receives Nasdaq Notice Regarding Form 10-Q CELU -7.46% GlobeNewswire
May-09
Celularity Announces Full Year 2024 Operating and Financial Results CELU GlobeNewswire
Affiliate • Advertise • API and Exports • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information
Stock quotes delayed by 1 minute. Futures and options delayed by 15 minutes.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)